IN8bio, Inc. (INAB)

IN8bio Statistics

Total Valuation

IN8bio has a market cap or net worth of $10.89 million. The enterprise value is $3.16 million.

Market Cap	10.89M
Enterprise Value	3.16M

Important Dates

The last earnings date was Thursday, November 6, 2025, after market close.

Earnings Date	Nov 6, 2025
Ex-Dividend Date	n/a

Share Statistics

IN8bio has 4.63 million shares outstanding. The number of shares has increased by 127.93% in one year.

Current Share Class	4.63M
Shares Outstanding	4.63M
Shares Change (YoY)	+127.93%
Shares Change (QoQ)	+10.16%
Owned by Insiders (%)	25.10%
Owned by Institutions (%)	13.96%
Float	2.41M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.82
P/TBV Ratio	0.83
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 6.91, with a Debt / Equity ratio of 0.22.

Current Ratio	6.91
Quick Ratio	6.28
Debt / Equity	0.22
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -189.72% and return on invested capital (ROIC) is -87.12%.

Return on Equity (ROE)	-189.72%
Return on Assets (ROA)	-80.39%
Return on Invested Capital (ROIC)	-87.12%
Return on Capital Employed (ROCE)	-139.74%
Revenue Per Employee	n/a
Profits Per Employee	-$1.15M
Employee Count	18
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -74.94% in the last 52 weeks. The beta is -0.01, so IN8bio's price volatility has been lower than the market average.

Beta (5Y)	-0.01
52-Week Price Change	-74.94%
50-Day Moving Average	1.85
200-Day Moving Average	2.76
Relative Strength Index (RSI)	61.19
Average Volume (20 Days)	726,997

Short Selling Information

The latest short interest is 38,725, so 0.84% of the outstanding shares have been sold short.

Short Interest	38,725
Short Previous Month	21,609
Short % of Shares Out	0.84%
Short % of Float	1.61%
Short Ratio (days to cover)	0.72

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-21.05M
Pretax Income	-20.66M
Net Income	-20.66M
EBITDA	-19.16M
EBIT	-21.05M
Earnings Per Share (EPS)	-$6.36

Balance Sheet

The company has $10.69 million in cash and $2.96 million in debt, with a net cash position of $7.73 million or $1.67 per share.

Cash & Cash Equivalents	10.69M
Total Debt	2.96M
Net Cash	7.73M
Net Cash Per Share	$1.67
Equity (Book Value)	13.19M
Book Value Per Share	2.87
Working Capital	10.07M

Cash Flow

In the last 12 months, operating cash flow was -$14.60 million and capital expenditures -$33,000, giving a free cash flow of -$14.63 million.

Operating Cash Flow	-14.60M
Capital Expenditures	-33,000
Free Cash Flow	-14.63M
FCF Per Share	-$3.16

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

IN8bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-127.93%
Shareholder Yield	-127.93%
Earnings Yield	-189.68%
FCF Yield	-134.37%

Analyst Forecast

The average price target for IN8bio is $108.00, which is 4,495.75% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$108.00
Price Target Difference	4,495.75%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on June 6, 2025. It was a reverse split with a ratio of 1:30.

Last Split Date	Jun 6, 2025
Split Type	Reverse
Split Ratio	1:30

Scores

Altman Z-Score	n/a
Piotroski F-Score	2